H Fridborg
About
In The Last Decade
H Fridborg
20 papers receiving 464 citations
Peers
Comparison fields: 5 of 77
- Molecular Biology 239
- Oncology 225
- Surgery 60
- Public Health, Environmental and Occupational Health 53
- Genetics 50
Countries citing papers authored by H Fridborg
This map shows the geographic impact of H Fridborg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H Fridborg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H Fridborg more than expected).
Fields of papers citing papers by H Fridborg
This network shows the impact of papers produced by H Fridborg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H Fridborg. The network helps show where H Fridborg may publish in the future.
Co-authorship network of co-authors of H Fridborg
This figure shows the co-authorship network connecting the top 25 collaborators of H Fridborg. A scholar is included among the top collaborators of H Fridborg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H Fridborg. H Fridborg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 36 | |
| 2 | 70 | |
| 3 | 7 | |
| 4 | 38 | |
| 5 | 24 | |
| 6 | Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) in the preclinical evaluation of cytotoxic drugs | 3 |
| 7 | 1 | |
| 8 | 35 | |
| 9 | Correlation of sensivity in vitro of human leukemia cells and systemic exposure at maximal tolerable dose (MTD) in man for cell cycle phase specific (type 2) anticancer drugs. | 1 |
| 10 | In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells. | 11 |
| 11 | 43 | |
| 12 | 22 | |
| 13 | 16 | |
| 14 | 71 | |
| 15 | 29 | |
| 16 | 1 | |
| 17 | P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells. | 9 |
| 18 | Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia. | 25 |
| 19 | 33 | |
| 20 | Cytotoxic action of cyclosporins on human tumor cell lines is not dependent on immunosuppressive activity. | 5 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.